Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Cabazitaxel in mCRPC (ProstyII)
NCT01558219Phase 2Completed
- Sponsor
- Tampere University Hospital
- Start
- Nov 2011
- Primary completion
- Dec 2014
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Tampere University Hospital. Started Nov 2011; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01558219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01558219.